OXELADIN CITRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H33NO3.C6H8O7
Molecular Weight	527.6044
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCOCCOC(=O)C(CC)(CC)C1=CC=CC=C1

InChI

InChIKey=KVKJFNUGVOFNGU-UHFFFAOYSA-N

InChI=1S/C20H33NO3.C6H8O7/c1-5-20(6-2,18-12-10-9-11-13-18)19(22)24-17-16-23-15-14-21(7-3)8-4;7-3(8)1-6(13,5(11)12)2-4(9)10/h9-13H,5-8,14-17H2,1-4H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C20H33NO3
Molecular Weight	335.4809
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB04822
Curator's Comment: Description was created based on several sources, including http://www.fda.gov.ph/consumers-corner/registered-drugs-2/337707-DR-X1387

Oxeladin citrate is a cough suppressant, is a highly potent and effective drug used to treat all types of cough of various etiologies. Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity. Oxeladine is a component of antitussive drug, Altussan, approved in Philippines.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cough 106 Sources: http://www.mims.com/philippines/drug/info/altussan	Palliative		Approved 8583	Altussan Approved Use For the relief of all types of cough w/ acute and chronic inflammation due to upper and lower respiratory tract infections

PubMed

Title	Date	PubMed
High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products.	2005-08	16023117

Patents

Sample Use Guides

In Vivo Use Guide

Cap Adult 1 cap. Syr Adult 1 tbsp (15 mL). Childn 1 tsp (5 mL). Infant ¼-½ tsp (1.25-2.5 mL). All doses to be taken 3 hrly.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:52:19 GMT 2025` Edited by `admin` on `Mon Mar 31 18:52:19 GMT 2025`
Record UNII	5AEV5C340C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXELADIN CITRATE

Common Name

English

OXELADIN HYDROGEN CITRATE

Preferred Name

English

Oxeladin citrate [WHO-DD]

Common Name

English

2-(2-DIETHYLAMINOETHOXY)ETHYL 2-ETHYL-2-PHENYLBUTYRATE DIHYDROGEN CITRATE

Systematic Name

English

OXELADIN CITRATE [MI]

Common Name

English

NSC-759231

Code

English

OXELADIN CITRATE [MART.]

Common Name

English

OXELADIN DIHYDROGEN CITRATE

Common Name

English

OXELADIN HYDROGEN CITRATE [EP MONOGRAPH]

Common Name

English

OXELADIN CITRATE [JAN]

Common Name

English

OXELADINE CITRATE

Common Name

English

BENZENEACETIC ACID, .ALPHA.,.ALPHA.-DIETHYL-, 2-(2-(DIETHYLAMINO)ETHOXY)ETHYL ESTER, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)

Systematic Name

English

Code System Code Type Description

CAS

52432-72-1